Boute P, Page C, Biet A, Cuvelier P, Strunski V, Chevalier D
Service d'ORL et chirurgie cervico-faciale, CHU d'Amiens, Centre Hospitalier Nord, place Victor-Pauchet, 80054 Amiens cedex, France.
Service d'ORL et chirurgie cervico-faciale, CHU d'Amiens, Centre Hospitalier Nord, place Victor-Pauchet, 80054 Amiens cedex, France.
Eur Ann Otorhinolaryngol Head Neck Dis. 2014 Nov;131(5):283-7. doi: 10.1016/j.anorl.2013.10.003. Epub 2014 Oct 3.
The study was designed to assess the prevalence, management and survival of patients with simultaneous squamous cell carcinomas of the oral cavity and hypopharynx (OC/HP).
A multicenter, retrospective study (2 university hospitals) was conducted between 2003 and 2007 on a series of 96 patients with simultaneous squamous cell cancers of the OC/HP.
A total of 88 men and 8 women were included in the study: 81 patients presented double sites, 14 presented triple sites and one presented quadruple sites. The tumour sites most frequently observed were: hypopharynx in 61% of cases (involving the pyriform sinus in 42% of cases) and the oropharynx in 59% of cases (involving the palatine tonsil in 30% of cases). Upper aerodigestive tract endoscopy under general anaesthesia revealed a simultaneous lesion not suspected on clinical examination in 45% of patients: the site discovered on endoscopy was hypopharyngeal in 2 out of 3 cases; the tumour was classified T1 or T2 in 95.5% of cases. Patients treated simultaneously for all sites had a better prognosis than patients in whom each tumour was treated separately. The 5-year specific survival was 34% and the 5-year overall survival was 28%.
The prevalence of simultaneous squamous cell carcinomas of the oral cavity and hypopharynx ranges between 1 to 7.4% in the literature and was 4.6% in the present series. A common treatment strategy for each of the patient's tumours appears to be superior to the current theoretical approach that consists of considering each tumour separately.
本研究旨在评估口腔和下咽同时发生鳞状细胞癌(OC/HP)患者的患病率、治疗情况及生存率。
于2003年至2007年在两家大学医院开展了一项多中心回顾性研究,纳入了96例口腔和下咽同时发生鳞状细胞癌的患者。
本研究共纳入88例男性和8例女性患者:81例患者为双原发部位,14例为三原发部位,1例为四原发部位。最常观察到的肿瘤部位为:下咽占61%(梨状窝占42%),口咽占59%(腭扁桃体占30%)。全身麻醉下的上消化道内镜检查显示,45%的患者存在临床检查未怀疑的同时性病变:内镜检查发现病变位于下咽的情况占2/3;95.5%的病例肿瘤被分类为T1或T2。对所有部位同时进行治疗的患者预后优于对每个肿瘤分别进行治疗的患者。5年特异性生存率为34%,5年总生存率为28%。
文献报道口腔和下咽同时发生鳞状细胞癌的患病率在1%至7.4%之间,本系列研究中的患病率为4.6%。针对患者每个肿瘤的共同治疗策略似乎优于目前分别考虑每个肿瘤的理论方法。